Daehan New Pharm Co. Ltd (054670) — Cash Flow Reinvestment Rate
Daehan New Pharm Co. Ltd (054670) has a Cash Flow Reinvestment Rate of 2.61x as of September 2025, reinvesting ₩11.53 Billion (capex ₩11.53 Billion ) from operating cash flow of ₩4.43 Billion. Check earnings quality score of Daehan New Pharm Co. Ltd to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Daehan New Pharm Co. Ltd Cash Flow Reinvestment Rate (2011–2024)
Historical reinvestment intensity for Daehan New Pharm Co. Ltd across 12 annual periods. Explore long-term investment intensity of Daehan New Pharm Co. Ltd to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for Daehan New Pharm Co. Ltd (2011–2024)
Year-by-year capital reinvestment analysis for Daehan New Pharm Co. Ltd. For live market cap and broader valuation context, see Daehan New Pharm Co. Ltd market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 3.35x | ₩63.38 Billion | ₩18.95 Billion | ₩34.26 Billion | ▲ +89.1% |
| 2023 | 1.77x | ₩22.23 Billion | ₩12.57 Billion | ₩9.93 Billion | ▲ +141.5% |
| 2022 | 0.73x | ₩10.44 Billion | ₩14.25 Billion | ₩3.51 Billion | ▼ -50.4% |
| 2021 | 1.48x | ₩24.48 Billion | ₩16.58 Billion | ₩10.55 Billion | ▲ +30.2% |
| 2020 | 1.13x | ₩15.36 Billion | ₩13.55 Billion | ₩9.46 Billion | ▲ +176.9% |
| 2019 | 0.41x | ₩9.38 Billion | ₩22.89 Billion | ₩9.08 Billion | ▲ +372.5% |
| 2018 | 0.09x | ₩1.77 Billion | ₩20.47 Billion | ₩1.73 Billion | ▼ -90.5% |
| 2016 | 0.91x | ₩7.96 Billion | ₩8.75 Billion | ₩4.57 Billion | ▲ +81.6% |
| 2015 | 0.50x | ₩3.91 Billion | ₩7.80 Billion | ₩3.86 Billion | ▼ -28.2% |
| 2014 | 0.70x | ₩6.99 Billion | ₩10.02 Billion | ₩6.69 Billion | ▼ -88.4% |
| 2012 | 6.00x | ₩1.54 Billion | ₩256.82 Million | ₩1.24 Billion | ▲ +1330.2% |
| 2011 | 0.42x | ₩1.43 Billion | ₩3.42 Billion | ₩1.20 Billion | — |